Enantia at DCAT week

Enantia at DCAT week


Home > News > Enantia at DCAT week 2024

Enantia will be at the DCAT week to discuss with our US customers our services in chemistry and solid form development.

Enantia at DCAT Week 2024

February 15th, 2024

Enantia will be in New York city for this year’s edition of the DCAT week, taking place between March 18th and 21st 2024.

For over two decades we have been dedicated to fulfill our clients’ requirements on Small Organic Molecules through extensive chemical research and development, encompassing even Highly Potent APIs (HPAPIs). Take advantage of our broad expertise in Process Chemistry and Co-Crystallization Technology to move your chemical development forward.

Arrange a meeting with us through info@enantia.com or via LinkedIn.

Looking forward to speaking with you in NYC!

Flow chemistry available at Enantia

Flow chemistry available at Enantia


Home > News > Flow chemistry available at Enantia

Flow Chemistry equipment at Enantia for chemical development services like route scouting, optimization and scale-up. CMC services. Medicinal chemistry services.

Enantia is proud to announce the inclusion of continuous flow chemistry for our Process Chemistry projects and our Medicinal Chemistry services

February 12th, 2024

Enantia is proud to offer flow chemistry as part of our services in medicinal chemistry and CMC development.

Flow chemistry has been a well-established technology in the petrochemical and bulk commodity industries for decades. Surprisingly, it has not been until recent years that it has gained an increasingly important role and interest in the manufacture of complex active pharmaceutical ingredients (APIs). As a result of this, flow chemistry has become a powerful enabling tool, complementary to traditional batch manufacturing, for the pharmaceutical and fine chemical industries to develop more sustainable, safe, environmentally friendly and efficient chemical processes.

With the inclusion of flow chemistry to our portfolio of innovative technologies, we aim to provide comprehensive services in the development of routes of synthesis, process optimization and scale up of key intermediates and API manufacturing processes. This will complement and strengthen our activities in chemistry, manufacturing, and control (CMC).

The advantages of flow chemistry enable the successful performance of processes that, otherwise, would not be feasible at industrial scale in batch reactors. For example:

  • Processes requiring accurate controlled conditions
  • Processes with hazardous reagents or intermediates
  • Processes carried out under extreme conditions of temperature or pressure
  • Photocatalytic processes

In addition, flow chemistry integrates into Enantia’s medicinal chemistry platform as an additional tool to support the company’s MedChem services.

Enantia offers the flow chemistry services in partnership with Alza&Associates, a sustainable chemistry consulting company. We combine Enantia’s extensive experience in chemical R&D of drug substances with A&A’s extensive experience and deep flow chemistry knowledge to provide a unique, industry-oriented service.

Read more here about our flow chemistry capabilities and equipment.

Enantia’s Presence at BioSpain 2023

Enantia’s Presence at BioSpain 2023


Home > News > Enantia’s Presence at BioSpain 2023

Enantia attended the current edition of BioSpain, the main national biotech event and one of the most important in Europe

Enantia’s presence at BIOSPAIN 2023

September 29th, 2023

Enantia attended the current edition of BIOSPAIN, the main national biotech event and one of the most important in Europe, attracting over 850 entities seeking collaboration opportunities in the field of drug development.

From September 26th to 28th, we engaged with the dynamic biotech community and explore ground-breaking opportunities for collaboration.

We discussed our services in Medicinal Chemistry (design and synthesis of focused libraries), Process Chemistry (such as route scouting and CMC support), Solid Form Screening and Development (optimizing candidate properties, improving IP and obtaining purification processes) and Solid Form Analysis (for a detailed understanding of the solid phase in the development and manufacturing of APIs and fine chemicals).

If you missed connecting with us at the event, discover how Enantia can support your project at info@enantia.com.

We’re committed to advancing innovation in drug discovery in the biotech and pharma industry!

Enantia at BOS Basel 2023

Enantia at BOS Basel 2023

Home > News > Enantia at BOS Basel 2023
Enantia at CPhI

Enantia at BOS Basel 2023

July 4th and 5th, 2023

Enantia is attending this year’s edition of BOS Basel, taking place the 4th and 5th of July.

As a leading CRO in Process Chemistry, Solid Form Development and Medicinal Chemistry, we have been committed to meet our clients’ needs regarding the research and development of Small Organic Molecules, including Highly Potent APIs, since 2003. Our strengths as key providers of CMC services are:

  • Optimizing, scaling-up and impurity profiling of routes of synthesis
  • Purification technologies based on crystallizations and cocrystallizations
  • Solid Form Development (being pioneers in the screening of cocrystals) and Solid Form Analysis

Find us through the partnering platform and at info@enantia.com. We will be glad to meet you to explore new synergies together.

See you in Basel!

Enantia has once again been granted the CIR from the French authorities

Enantia has once again been granted the CIR from the French authorities


Home > News > CIR granted to Enantia

CIR Enantia CRO cocrystals chemical development

Enantia has once again been granted the CIR from the French authorities

January 25th, 2023

The French Ministry of Higher Education and Research has granted Enantia with the Crédit d’Impôt Recherche (CIR) (i.e., R&D tax credit) for a further three-year period: 2023, 2024 and 2025.

Thanks to the support of Crédit d’Impôt Recherche, French companies can incur research and development costs and be partially reimbursed for these expenses. The objective of this measure is to promote business innovation and competitiveness at national and international level.

We are glad to share this great news with our French customers, especially those with a strong R&D activity. This includes pharmaceutical companies, biotechs, CDMOs and CMOs, which can benefit from our CIR accreditation in all our services, such as medicinal chemistry, chemical development, solid state development and solid form analysis.

You can find our CIR accreditation here.

Christmas greetings 2022

Christmas greetings 2022


Home > News > Christmas 2022 at Enantia

Enantia's Crystals

We wish you all a Merry Christmas and a Happy New Year!

December 21th, 2022

May Christmas bring happiness and health to all of you and your loved ones.

We would like to express our deepest appreciation for the trust you have placed in us during this 2022.

Let’s continue to work together in the coming new year!

Enantia at ALBA Synchrotron workshop

Enantia at ALBA Synchrotron workshop


Home > News > Enantia at the 2022 ALBA synchrotron symposium
Front page ALBA meeting

Enantia at the ALBA Synchrotron workshop

June 15th, 2022

Next June 17th the ALBA Synchrotron will host the workshop: “ALBA Synchrotron Applications for the Pharmaceutical Industry” to show pharmaceutical companies the applications of synchrotron light. Studies at the synchrotron are a valuable ally for the pharmaceutical sector, for example, during the design of new drugs or the characterization of active ingredients in the final formulation.

The conference is aimed at managers and members of the R&D&i team from pharmaceutical and biomedical companies who wish to know more about how a synchrotron works and its main industrial applications.

Enantia is a frequent user of the ALBA synchrotron which has allowed us to build a solid experience exploiting its high sensitivity X-ray beam lines. We leverage our expertise to, for example, detect and quantify very small percentages of crystalline forms in complex matrixes including drug formulations, to determine the absolute configuration of an API and to confirm the formation of a cocrystal or a salt. Experiments performed by Enantia at the ALBA synchrotron are also used to support IP Hatch-Waxman Act litigation strategies both by plaintiff and defendant parties in Paragraph IV trials.

During the meeting, experienced staff from companies will present case studies involving the use of the ALBA synchrotron X-ray beam lines. Joan Farran, the head of Enantia’s Solid-State Analysis department, will be talking on behalf of Enantia about real examples of X-ray diffraction analysis that allowed advances in various stages of the development of pharmaceuticals products.

The event will also include a visit to the facilities as well as a networking lunch.

Attendance is free but registration is required through this website: https://indico.cells.es/e/workshopindustrialsalud

The event is organised in collaboration with BIOCAT and with the support of the European project LEAPS-Innov.

Enantia co-organises the 2022 SEQT Summer School

Enantia co-organises the 2022 SEQT Summer School



Home > News > Enantia co-organises the 2022 SEQT summer school


Enantia co-organises the 2022 SEQT Summer School on medicinal chemistry and chemical biology in drug discovery

May 18th, 2022

We are pleased to share our consolidated expertise in drug discovery with young and passionate scientists by co-organising, along with the Spanish Society of Medicinal Chemistry (SEQT), the Seventh SEQT Summer School, which this year has been certified by the European Federation for Medicinal Chemistry and Chemical Biology (EFMC).

The event will take place next July 19-21th 2022 in the Barcelona Science Park and it brings a great opportunity for approaching the pharma industry to young researchers working in the field of chemistry and life sciences. The participants will learn about the state of the art and new trends in drug discovery and development with experts from Almirall, Novartis, Merck, Janssen, FAES Farma, Gate2Brain and Enantia, amongst others.

To facilitate an optimal interaction with the speakers, the number of attendees is limited, therefore early registrations are strongly encouraged. The deadline for registrations is on the 15/06/22.



New HPAPIs facilities

New HPAPIs facilities

Home > News > New HPAPIs facilities

Enantia extends its service portfolio to HPAPIs

March 28th, 2022

Enantia is proud to announce the commission of new dedicated facilities to work with HPAPIs in solid forms R&D projects.

High potency active pharmaceutical ingredients (HPAPIs) exert their activity at a very low dosage. Though the definition of a HPAPI is yet to be harmonized[1], HPAPIs can be defined based on the therapeutic dose as a pharmacologically-active ingredient with biological activity at approximately 15 μg/kg of body weight or below in humans, or a daily dose of 1 mg/day or below[2].

The global market of HPAPIs is forecasted to grow from 21.2 USD billions in 2021 to 32.17 USD billions in 2026 at an annual increase of 8.7%[3]. Within this category of compounds, the generic drug segment is the one expected to be the fastest growing[4]. Some of the factors attributing to its growth are patent expiry of HPAPI branded drugs and the rising number of patients in developing economies.

Therefore, undertaking a solid form screening to develop a new, non-infringing alternative solid form of a HPAPI can be a highly convenient strategy when aiming at developing new generics, as well as to extend IP rights for new chemical entities (NCE).

Hence, screening for new cocrystals, polymorphs, solvates and salts is a powerful tool that allows to competitively market new forms of a drug. In this sense, FDA[5] and EMA’s[6]  regulatory guidelines have set a clear and simple path to the filing of both NDA and ANDA using cocrystals as the solid form of the API.

Enantia’s new facilities allow working with HPAPIs having Operational Exposure Limits (OEL) down to 100 ng/m3, which comprises the overwhelming majority of HPAPIs. Moreover, an additional new X-ray powder diffractometer, working both in transmission and reflection mode, has been installed specifically for HPAPIs analysis.

This means that Enantia also offers for high potency APIs its expertise in:

Moreover, Enantia plans to soon extend all the necessary containment equipment and procedures to the Chemical R&D and Medicinal Chemistry departments in order to execute projects also involving HPAPIs.

If you want to know more about solid state R&D services for HPAPIs keep reading here.


[1] Walsh, Andrew & Barle, Ester. (2017). Are high potency active pharmaceutical ingredients (HPAPI) also high risks for cross-contamination? Chemistry Today. 35.

[2] NTP1104. Industria farmacéutica: clasificación de principios activos en categorías. Actualiza NTP798.

[3] Global HPAPI Market Size, Share, Trends, COVID-19 Impact & Growth Analysis Report – Segmented By Type (Innovative HPAPI’s & Generic HPAPI’s), Synthesis (Biotech HPAPI’s & Synthetic HPAPI’s), Therapeutic Application & Region – Industry Forecast (2022 to 2027), January, 2022, ID: 2903, Pages: 175.

[4] High Potency Active Pharmaceutical Ingredients Market Size, Share & Trends Analysis Report By Product (Synthetic, Biotech), By Manufacturer Type (In-house, Outsourced), By Drug Type, By Application, By Region, And Segment Forecasts, 2021 – 2028. Published Date: Sep, 2021, Report ID: 978-1-68038-563-2, Number of Pages: 140.

[5] Regulatory Classification of Pharmaceutical Co-Crystals Guidance for Industry U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) February 2018 Pharmaceutical Quality/CMC Revision 1.

[6] Reflection paper on the use of cocrystals of active substances in medicinal products EMA/CHMP/CVMP/QWP/284008/2015.

Picture: Enantia’s HPAPIs dedicated XRPD working in transmission and reflection modes

New Cocrystal Discovered at Enantia Approved by the FDA

New Cocrystal Discovered at Enantia Approved by the FDA


Home > News >New Cocrystal Discovery at Enantia Approved by the FDA

Asymmetric unit of the cocrystal of tramadol hydrochloride and celecoxib

New cocrystal discovered at Enantia approved by the FDA

February 14th, 2022

A new API-API pharmaceutical cocrystal discovered at Enantia for ESTEVE Pharmaceuticals and commercialised with the name of SEGLENTIS® has been recently approved by the FDA for its use in the United States.

The U.S. Federal Food & Drug Administration (FDA) has recently approved SEGLENTIS® (October 15th, 2021) for its use as acute pain treatment in adults. This new drug is an innovative API-API pharmaceutical cocrystal composed of two already commercial analgesics. Celecoxib and racemic tramadol hydrochloride are presented in a 1:1 stoichiometric ratio cocrystal and formulated as a tablet.

The discovery and development of this novel cocrystal has been carried out at ENANTIA for ESTEVE Pharmaceuticals. The drug has been licensed to KOWA Pharmaceuticals America Inc. for its commercialization in the United States, with a launch planned for this year 2022.

This announcement highlights the increasing relevance of the cocrystallization technology as an effective strategy for the design of new drugs. The improvement of some key physicochemical and pharmacokinetic properties of an API can be achieved through the obtention of a new solid form such as a cocrystal. Because of this, and the generation of new IP that cocrystals allow, pharmaceutical companies resort to this approach to launch new drugs and to manage the lifecycle of existing ones.

Both USA (FDA) and European (EMA) regulatory agencies have published their current guidance on the regulatory aspects of the use of pharmaceutical cocrystals in drugs. These guidelines strengthen the use of pharmaceutical cocrystals for drug development. In this sense, SEGLENTIS® adds to the list of already approved pharmaceutical cocrystals being ENTRESTO®, developed by NOVARTIS and approved by the FDA and the EMA in 2015, one of the first API-API cocrystals to reach the market.

The approval of SEGLENTIS® is fantastic news for the pharma industry in general and for the R&D companies specialised on new solid form development, in particular. ENANTIA has been one of the introducers of cocrystals and the study of their application in different fields such as pharma and nutraceutical products, as well as in chemical process development. This drug approval evidences ENANTIA’s expertise on cocrystal engineering gained over almost 20 years since its foundation, demonstrated by the appearance of Enantia in more than 25 patent applications related to the study of cocrystals either as applicant or as inventor.

If you want to learn more about cocrystals, keep reading here.



Picture: Asymmetric unit of the APIAPI cocrystal formed by tramadol·HCl and celecoxib. https://doi.org/10.1021/acs.cgd.6b01848